New Study Finds Psychedelic Nasal Spray Could Offer Rapid Relief From Severe Depression: jlsfund.substack.com/p/new-s… @ataibeckley #depression #psychedelics
FDA Clears Nationwide Recruitment for Brain Implant That Helps Paralyzed Patients Speak Again: jlsfund.substack.com/p/fda-c… @paradromics
JLS Fund retweeted
A fascinating UCSF study on psilocybin for Parkinson's.
The potential for psychedelics to reduce mitochondrial stress and inflammation is one of the most exciting areas of emerging research in our field.
If you want to dig deeper into the science, check out the work of Dr. Chuck Nichols at LSU.
IMHO, we should be adding these biomarkers to human psychedelic studies, as the implications are just massive.
If you're a researcher in the field. I'd love to hear your thoughts on the most relevant, cost-effective measures we could be adding to new studies.
cc. @MitoPsychoBio @EllenBradleyMD
Paradromics Partners With Siemens to Improve Brain Implant Surgery: jlsfund.substack.com/p/parad… @paradromics #bci #braincomputerinterface
JLS Fund retweeted
R.I.S.E. Summit
November 12th
Irvine California
Exploring psychedelic treatments for addiction recovery
I have one free registration to give away to the most deserving : )
make your case.
etheridgefoundation.org/rise…
New Non-Opioid Pain Drug Delivers Promising Phase 3 Results: jlsfund.substack.com/p/new-n… #opioids
Arrowhead Pharmaceuticals' Experimental Alzheimer's Drug Delivers Promising Early Results: jlsfund.substack.com/p/arrow… @ArrowheadPharma #alzheimers
Eton Pharmaceuticals and Aquestive Therapeutics Team Up to Bring New Epilepsy Treatment to Patients: jlsfund.substack.com/p/eton-… #epilepsy
IGC Pharma Unveils New AI Platform to Help Identify Alzheimer's Risk Earlier: jlsfund.substack.com/p/igc-p… @IgcPharmaSAS #alzheimers
JLS Fund retweeted
Ontario Research Hospital Receives $2M in Gifts for Psychedelics Centre
St Joseph’s Healthcare Hamilton has received $1M apiece from two philanthropic sources to support its Centre for Health Innovation and Research in Psychedelics, or CHIRP. The centre is currently running three trials: psilocybin for chronic pain and two studies looking at psilocybin for cannabis use disorder.
Read more on our website: psychedelicalpha.com/news/p%…
JLS Fund retweeted
I knew Jordan Kronick from his documentary "Ecstasy Rising"
here's his latest doc, Peaking
peakingdocumentary.com/
JLS Fund retweeted
Breaking
lifespan.com/blogs/magazine/…
UCSF to Test Psilocybin as a Treatment for Methamphetamine Addiction: jlsfund.substack.com/p/ucsf-… #addiction
Viatris Bets $1.65 Billion on Alternatives to Opioid Painkillers: jlsfund.substack.com/p/viatr… @ViatrisInc @PaciraBio #opioids
PharmAla and Rua Bioscience Bring Medicinal MDMA to New Zealand: jlsfund.substack.com/p/pharm… @PharmAlaBiotech #MDMA #PTSD
JLS Fund retweeted
NIMH Grant Opportunity
The National Institute of Mental Health (NIMH) is set to share a grant opportunity to support the implementation of ‘rapid-acting psychotropic interventional drugs’, or RAPIDs, which includes ketamine and psychedelics.
The program is geared around real-world effectiveness and expects to award $20M across three projects.
It will be posted tomorrow, October 10th.
Read more on our website: psychedelicalpha.com/news/p%…
This Technology Could Help Scientists Identify Failed Brain Drugs Before Human Trials: jlsfund.substack.com/p/this-…
New Parkinson’s Drug Succeeds in Phase 3 Trial: jlsfund.substack.com/p/new-p… @cerevance #parkinsons
JLS Fund retweeted
Next week, leading psychedelic drug developers will discuss the current state and future prospects of the field at The Psychedelic Healthcare Forum in New York City.
AJ Cannon (AbbVie), Srinivas Rao (AtaiBeckley / Eli Lilly), and Dan Karlin (Definium Therapeutics) will participate in a conversation moderated by Kyle LaHucik (Endpoints).
Could an App Help Treat Schizophrenia? The FDA Says Yes: jlsfund.substack.com/p/could… #schizophrenia